On Oct. 26, 2006, the U.S. Food and Drug Administration approved telbivudine, which will be marketed in the U.S. under the brand name Tyzeka, for the treatment of chronic hepatitis B in adults. The new drug is indicated as a once-daily oral therapy and studies have demonstrated that Tyzeka rapidly and profoundly suppresses HBV replication. It will be marketed as Sebivo outside the U.S.